Alternatives to Givlaari If You Can't Fill Your Prescription

Givlaari (givosiran) has transformed care for many people living with acute hepatic porphyria (AHP). But when insurance denies coverage, prior authorization stalls, or access to a specialty pharmacy and administration site is simply not possible, patients are left asking: what are my alternatives?

The honest answer is that the alternatives to Givlaari are more limited than for most conditions — AHP is rare, and treatment options reflect that. But there are meaningful options. This guide covers all of them honestly.

Why AHP Alternatives Are Limited

Acute hepatic porphyria is caused by genetic mutations that disrupt heme production in the liver, leading to accumulation of toxic compounds (ALA and PBG) that trigger attacks. The FDA has approved only two medications specifically for AHP: Givlaari and Panhematin (hemin). All other management strategies are supportive or aimed at preventing attacks through lifestyle and trigger avoidance. There is no pill you can take instead.

Option 1: Panhematin (Hemin for Injection)

Panhematin (hemin for injection), manufactured by Recordati Rare Diseases, is the longest-standing FDA-approved treatment for AHP. It has been available since 1983. Unlike Givlaari, which prevents attacks, Panhematin works by treating active attacks — though it is also used off-label as a preventive (prophylactic) therapy.

How it works: Hemin repletes the regulatory heme pool in the liver, which suppresses ALAS1 activity through negative feedback — reducing ALA and PBG levels. It is given intravenously, typically 3 to 4 mg/kg per day for four consecutive days during an acute attack. Prophylactic use typically means weekly or monthly infusions.

Pros: Less expensive than Givlaari (though still costly as a specialty infusion); FDA-approved; widely available at hospitals and infusion centers; does not require the same level of prior authorization for acute attack treatment.

Cons: Must be given intravenously (IV), requiring infusion center access; can cause phlebitis and vein damage over repeated use; associated with transient coagulopathy and iron overload with repeated dosing; must be given for 4 days per attack; it does not address the underlying disease driver the way Givlaari does. Clinical trials showed Givlaari reduced attacks by about 70%, meaning patients on Givlaari use far less hemin overall.

Option 2: Glucose and Carbohydrate Loading

For mild acute attacks, high-carbohydrate intake can help suppress ALAS1 activity. Glucose raises insulin levels, which inhibit the transcriptional coactivator PGC-1α and reduce ALAS1 expression. In a mild attack, oral carbohydrate loading (300–500 grams per day) is sometimes tried before progressing to hemin. IV glucose (10% dextrose) may be administered during hospitalizations.

This approach is not effective for moderate or severe attacks and should never delay hemin administration when attacks escalate. It is supportive, not curative.

Option 3: Trigger Avoidance and Lifestyle Modification

Many AHP attacks are triggered by identifiable factors. While this isn't a treatment, rigorous trigger avoidance reduces attack frequency for many patients. Common triggers include:

• Certain medications (barbiturates, sulfonamides, hydantoins, rifampin, some anti-epileptics — always check the American Porphyria Foundation's drug list)
• Caloric restriction, fasting, or very low-carbohydrate diets
• Alcohol consumption
• Endogenous hormones (attacks tied to the menstrual cycle are common in women with AHP)
• Infections, physical or emotional stress, and surgery

Option 4: Hormonal Management (For Women)

Women who experience cyclical AHP attacks tied to their menstrual cycle may benefit from hormonal management. GnRH analogues (given under close specialist supervision) can suppress hormonal fluctuations that trigger attacks. Low-dose oral contraceptives are sometimes used but can also trigger attacks in some patients, so specialist input is critical. This is an area where individual response varies significantly.

Option 5: Liver Transplantation (Last Resort)

In extreme cases of severe, recurrent AHP attacks that don't respond to other treatments, liver transplantation has been performed. Because the liver is the site of the defective enzyme in AHP, transplantation can cure the metabolic defect. However, it carries significant operative risk, requires lifelong immunosuppression, and involves waiting for a donor organ. It is reserved for the most severe, refractory cases.

What If Givlaari Is Temporarily Unavailable?

If your Givlaari dose is delayed due to insurance or logistics, contact your doctor immediately. IV hemin (Panhematin) can bridge you through coverage gaps. The Alnylam Assist® Bridge Program can also provide free Givlaari while your insurance authorization is pending. medfinder can help locate specialty pharmacies and sites of care that can accommodate your prescription quickly when you are navigating access challenges.

Comparing the Main Options

Givlaari: Once-monthly subcutaneous injection; prevents attacks at the source by silencing ALAS1; requires specialist prescriber, prior auth, specialty pharmacy. Reduces attacks by ~70%.

Panhematin: IV infusion; treats acute attacks or can be used prophylactically; available at most hospitals; less expensive than Givlaari but still costly; associated with vein damage over time.

Always work with your AHP specialist to determine the best option for your specific situation. If you are struggling to access Givlaari, see our guide on why Givlaari is hard to find and what to do.